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To understand the structure-function relationship of muscle-regulatory-protein isoforms, mutations, and posttranslational mod-
iﬁcations, it is necessary to probe functional eﬀects at the level of the protein-protein interaction. Traditional methodologies
assessing such protein-protein interactions are laborious and require signiﬁcant amounts of puriﬁed protein, while many current
methodologies require costly and specialized equipment or modiﬁcation of the proteins, which may aﬀect their interaction. To
address these issues, we developed a novel method of microplate-based solid-phase protein-binding assay over the recent years.
This method assesses speciﬁc protein-protein interactions at physiological conditions, utilizes relatively small amounts of protein,
is free of protein modiﬁcation, and does not require specialized instrumentation. Here we present detailed methodology for
the solid-phase protein-binding assay with examples that we have successfully applied to quantify interactions of myoﬁlament-
regulatory proteins. We further provide considerations for optimization of the assay conditions and its broader application in
studies of other protein-protein interactions.
1.Introduction
To ultimately understand the structure-function relationship
resulting from protein isoform variation, mutation, and
posttranslational modiﬁcation, one must be able to quantify
the functional eﬀect of the structural alteration on the inter-
action of the protein with its binding proteins. Traditional
methodologies used to investigate these interactions, such
as equilibrium dialysis and aﬃnity chromatography, rely on
large amounts of proteins, are time consuming, and are
labor intensive. While newer methodologies such as F¨ orster
resonance energy transfer or surface plasmon resonance
utilize less protein and can be of high throughput, they
rely on specialized, costly equipment and/or modiﬁcation of
the target protein with labeling that by itself may alter the
protein-protein interaction to be investigated.
Over the past number of years, we have developed a
novel microplate-based solid-phase protein-protein binding
assay. This assay requires no specialized equipment, uses
a minimal amount of protein, is rapid throughput, does
not rely on modiﬁcation of the target protein, and results
in quantitative measurements. In this assay one of the
proteins of interest is noncovalently immobilized to a solid
phase followed by incubation with a soluble binding partner
protein dissolved in a physiological solution. Binding is then
detected via an antibody against the soluble partner protein
using enzyme-linked immunosorbent assay (ELISA). Here
we present the detailed methodology for this novel high-
throughout protein-binding assay that we have successfully
employed for investigating myoﬁlament protein binding,
including troponin T to tropomyosin [1–3] and troponin
T to troponin I [1, 2, 4]. The assay is also highly eﬀective
in revealing the functional eﬀects of muscle myoﬁlament
protein alternative splicing variants [1, 2], phosphorylation
[5], restrictive proteolysis [4, 6], point mutations [7], as
well as the eﬀects of solution salt, metal ions, or pH
on myoﬁlament protein binding [8–11]. In addition, this
methodology has also been used to study the binding of
calponin [12, 13] and titin motifs [14] to F-actin. Beyond
these applications this assay can readily be extended to study2 Journal of Biomedicine and Biotechnology
the interactions of nonmuscle proteins. Any protein binding
paircanbeanalyzedprovidedthataspeciﬁcantibodyagainst
one of the proteins is available.
In this paper we ﬁrst discuss traditional protein-binding
assays and use this background to present the general
concepts of the microplate ELISA-based solid-phase protein-
binding assay. We then provide detailed methodology to
conduct a simple binary solid-phase binding assay. Finally,
we will discuss modiﬁcations expanding on the simple
binary binding experiment and optimization of the assay
conditions.
2.TraditionalProtein-ProteinBindingAssays
Classical assays to measure the interaction and binding
of one protein to another largely consist of two main
methodologies: (1) equilibrium dialysis and (2) aﬃnity
chromatography. These two methodologies rely on diﬀerent
principals to separate bound from nonbound interacting
proteins.
To determine the aﬃnity of two proteins for each other
by equilibrium dialysis, the experimental proteins of known
concentration are placed in two chambers separated from
each other by a membrane permeable to only one of the
proteins. The permeable protein is then allowed to diﬀuse
across the membrane and bind the nonpermeable protein.
Once the permeable protein achieves equilibrium between
the two chambers, its free concentration is determined in the
chamberlackingtheimpermeableprotein.Followingdialysis
oftheproteinpairatappropriateconcentrations,thebinding
aﬃnity of the pair can be determined. The dialysis can be
conducted with one or more variants of one of the two
proteins for comparison. Equilibrium dialysis, thus, provides
the aﬃnity of one protein for another at equilibrium
betweenassociationanddisassociationinsolution.Although
the data generated by equilibrium dialysis is quantitatively
informative, a major limitation of this method is that it
requires a size diﬀerence between the two binding proteins
tobedistinguishablebythedialysismembrane.Thedownfall
of this method also includes its labor-intensive nature and its
requirement for large amounts of the proteins.
The other commonly used traditional protein binding
assay is aﬃnity chromatography. Aﬃnity chromatography
requires immobilization of one protein to a support resin
that is usually packed into a column for chromatographic
analysis. The binding partner protein in solution is then
incubated with the protein-resin conjugate at suﬃcient
concentration and contact time to saturate its binding to
the immobilized protein. The binding aﬃnity between the
two proteins is then assessed by step or continuous gradient
elution with a buﬀer condition that weakens the protein-
protein interaction and the strength of elution necessary to
achieve peak dissociation of the bound protein determined.
Once the bound protein is completely eluted, the column
can be reequilibrated and a similar measurement conducted
for another or variant partner protein. Unlike the solution
steady-state binding measured in the equilibrium dialysis
method, aﬃnity chromatography measures a nonequilib-
rium disassociation rate from a maximally bound state.
Therefore, by its nature this assay only investigates the
disassociation characteristic of the two proteins. Further
drawbacks of this methodology include the measurement of
only relative aﬃnity and the necessity of chemically coupling
one of the proteins to a support resin, which by itself may
aﬀect the structure and function of the immobilized protein.
3.The MicroplateSolid-Phase
Protein-BindingAssay
The solid-phase protein-binding assay was developed as
an alternate methodology to asses association and dis-
association of protein-protein interactions using relatively
small amounts of protein without specialized equipment
[9]. The basis for the solid-phase protein-binding assay
is derived from ELISA-based methodology. The rational
for designing the protein-binding assay based on ELISA, a
well-established immunological assay, is that the antibody-
antigen interaction measured by various immunological
detection methods is basically a protein-protein interaction.
The assay consists of three main components. The ﬁrst is
immobilization of a protein to the wells of an assay plate
by noncovalent coating. The second is the protein-protein
interaction. The third is detection of the bound protein.
As a basis for our discussion, we will ﬁrst describe details
of a standard solid-phase protein-binding assay followed by
variants of the assay for extending its applications.
The simplest and most widely used format is the binary
binding assay that measures the interaction between two
proteins, one immobilized and the other free in solution.
This assay format is commonly used to compare the binding
interactions between an immobilized protein to two or more
variants of a soluble partner protein. However, the assay can
be designed such that the variant proteins are either in the
solution or immobilized position.
Although simple in its design, the binary assay format
(Figure 1(a)) demonstrates the basis of the solid phase
protein binding assay. In this experimental system a single
protein is noncovalently coated through absorption to the
well surface of a 96-well polystyrene (not polypropylene)
assay plate. Excess free protein in solution is subsequently
removed and the wells are washed. The remaining available
binding surfaces of the wells are blocked with a non-
interacting protein such as bovine serum albumin (BSA)
often together with a nonionic detergent. The plate is then
washed again followed by adding serial dilutions of the
binding partner protein to the wells and incubated allowing
equilibrium binding with the immobilized protein to be
reached. Remaining free protein in solution is then removed
followed by washes, and the portion of the partner protein
bound to the immobilized protein is quantiﬁed through
detection via an antibody speciﬁc to the binding partner
protein.
The detection employs an enzyme-linked antibody
approach. The enzyme, for example, horse radish peroxidase
(HRP), can be directly conjugated to the detecting antibody;
however, it is more convenient to use an enzyme-conjugated
second antibody. In this setting a primary antibody speciﬁ-
cally recognizing the bound protein is used as the detectingJournal of Biomedicine and Biotechnology 3
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Figure 1: Solid-phase protein-binding assay method. (a) Binary binding assay to quantify the interaction between an immobilized protein
and an interacting soluble protein. (1) The immobilized protein of interest is maximally coated into the wells of a 96 well assay plate. (2)
Unbound protein is removed by washing, and remaining surfaces blocked with a nonspeciﬁc protein. (3) The plate is washed, and binding
is evaluated by incubation with serial dilutions of a soluble interacting protein. (4) Following another wash to remove unbound interacting
protein, bound protein is detected by ELISA with a primary antibody against the interacting protein, a HRP-conjugated second antibody
and substrate development to quantify bound protein by absorbance. (b) Multilayer binding assay to quantify the interaction between an
immobilized protein and two related interacting soluble proteins. The multilayer protein binding is conducted similar to the binary binding
assay in (a) with the exception that, following binding of the ﬁrst soluble protein and washes, the wells are incubated with another protein
that binds the ﬁrst protein bound to the immobilized protein followed by ELISA quantiﬁcation. (c) Competitive binding assay to quantify
the interaction between an immobilized protein and an interacting soluble binding protein in the presence of varied amounts of a second
binding protein. Protein coating and blocking are conducted as in (a) and (b) with the exception that during the soluble protein binding
step, addition of the ﬁrst interacting protein of interest is conducted at a constant concentration in the presence of serial concentrations of
a competitive binding protein. Resultant binding of the constant concentration of the ﬁrst binding protein of interest to the immobilized
protein is then quantiﬁed by ELISA with a speciﬁc antibody. ELISA quantiﬁcation of the degree of competition will be detected by decreases
in the ﬁnal reading of absorbance.
antibody, and excess antibody is removed by washes. Subse-
quently an enzyme-conjugated second antibody recognizing
the detecting primary antibody is added for another step of
incubation followed by washes to remove excess second anti-
body. Finally, a substrate development reaction is conducted
and quantiﬁed using a microplate reader. The amount of the
bound enzyme-linked second antibody is in direct propor-
tion to the amount of bound primary detecting antibody
that is determined by the amount of the soluble partner
protein remaining bound to the immobilized protein. As the4 Journal of Biomedicine and Biotechnology
result of this direct relationship between the bound protein
and enzyme-linked secondary antibody, the intensity of the
color or ﬂuorescence product produced from the substrate
reaction is quantitatively dependent on the amount of the
solubleproteinremainingboundtotheimmobilizedprotein.
Byplottingthemicroplatereadingsagainsttheconcentration
of the free protein used in the equilibrium binding step, the
association AND disassociation features can be compared
between two or more variants of the proteins studied.
4.ExperimentalProcedure
As outlined above, Figure 1(a) shows the basic design of
the solid-phase protein-protein binding assay consisting of a
binary protein-binding experiment. The design of the binary
binding experiment investigates the binding characteristics
between two proteins, one of which is immobilized in the
wells of microplate and allowed to incubate with the binding
partner protein in solution. A thorough understanding of
this basic experimental setting will provide the foundation
for understanding more sophisticated designs derived from
it. For this reason we will ﬁrst present the binary binding
assay protocol and then the application of this methodology
to other designs.
As routinely employed in our laboratories, the binary
protein-binding experiment consists of coating the immobi-
lizedproteinthroughnoncovalentabsorption,bindingofthe
partner protein, and indirect ELISA detection of the protein
binding. This section will describe the detailed protocol to
conduct the binary binding assay similar to that described in
our previous publications [2, 9, 15].
4.1. Speciﬁc Materials
(i) 96-well polystyrene microtitering plates.
(ii) Multichannel pipette in the 100–200µLr a n g e .
(iii) Squishing wash bottle. A standard 500mL laboratory
wash bottle that can be used to provide a consistent
stream of wash buﬀer from a spout to ﬁll the wells of
the assay plate.
(iv) Buﬀer A (Buf A; 100mM KCl, 3mM MgCl2,a n d
10mM PIPES, pH 7.0) can be made as a 5x stock,
stableatroomtemperature.Thisbuﬀerisusedforthe
study of myoﬁlament proteins. It should be modiﬁed
according to the proteins to be studied. Neutral or
alkaline pH is required for proper coating of the
immobilized protein to the plate. A concentration
of 3–6M urea can be included for the coating of
less soluble proteins. Neutral pH should be used for
the urea-coating buﬀer to avoid carbamylation of
the protein. Most proteins will refold well following
immobilization during the blocking step after urea is
removed.
(v) Buﬀer T (Buf T; buﬀer A + 0.1% Tween-20).
(vi) Buﬀe rB( B u fB ;b u ﬀer T + 0.1% BSA).
(vii) Substrate solution (2,2 -azino-bis(3-ethylbenzo-thi-
azoline-6-sulfonic acid (ABTS)/H2O2 is used for
horseradish peroxidase-conjugated ﬁrst or second
antibody). 0.04% ABTS diammonium is dissolved
i n6 5 . 7m Mc i t r i ca c i dm o n o h y d r a t e ,3 4m Ms o d i u m
citrate dihydrate, pH 4.0, adjusted with sodium cit-
rate dihydrate. The substrate stock should be made in
autoclaved, deionized water with autoclaved tools to
avoid peroxidase contamination and stored at −20◦C
in aliquots of the volume for individual experiments.
Before use the substrate solution is brought to room
temperatureandimmediatelypriortoitsapplication,
0.03% H2O2 added.
(viii) Microplate reader capable of reading absorbance at
415nm or 405nm (for the ABTS substrate).
(ix) Primary antibody against the soluble protein to be
studied. Although it is necessary to have a speciﬁc
antibody against one of the proteins to be studied,
current methods of generating recombinant fusion
proteins with a tag, such as FLAG or His6−8, and the
availability of antibodies against such tags allow this
approach to be applied to a wide range of protein
interactions, overcoming the restriction from the
availability of a speciﬁc antibody.
(x) Horseradish peroxidase-conjugated second antibody
that recognizes the primary antibody species (e.g.,
goat anti-mouse IgG horseradish peroxidase conju-
gated secondary antibody) was used in our studies
employing mouse monoclonal primary antibodies.
4.2. Assay Design. A practical binary protein-binding assay
design consists of eight dilutions of the soluble binding
protein in triplicate. The 8 × 12 well format of the 96-
well microplate should be considered in the assay design.
For example, the immobilized protein can be arranged
in columns (A to H) and incubated with eight serial
dilutions of the soluble variant proteins. The assay design
should also include control columns for each variant protein
consisting of the serial diluted soluble protein incubated
in triplicate wells without immobilized protein. Figure 2
illustrates the 96-well microplate layout of a typical binary
binding experiment conducted in triplicate for two variant
soluble proteins.
4.3. Immobilization of Protein to the Microplate. It is pre-
ferred that the single partner protein is selected to be
the immobilized protein with the two or more variant
bindingproteinsincubatedinthesolublephase.Thisstrategy
will ensure a uniform level of the coated protein for the
comparison among the variants of the binding protein.
However, multiple variants of the proteins to be studied may
be coated under similar conditions for incubation with a
singlesolublepartnerproteinaswell.Standardcoatingofthe
immobilized protein occurs through absorption to the wells
of the assay plate based on hydrophobic interactions between
the plastic surface of the assay plate and the nonpolar amino
acid residues of the protein to be immobilized.
The coating of the immobilized protein onto the wells of
amicrotiterplateisperformedat100µL/wellwith2–5µg/mLJournal of Biomedicine and Biotechnology 5
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Figure 2: Representative design of a 96-well microtitering plate
assay for binary binding consisting of an immobilized protein
incubated with two variant soluble interacting proteins in 8 serial
concentrations of triplicate wells. Immobilized protein is equally
and maximally coated in the experimental wells, rows A to H and
columns 4 to 9. Columns 1 to 3 and 10 to 12 are left uncoated
(incubated with coating buﬀer only) as controls. Following coating
all wells are blocked, and the wells in columns 1 to 6 are incubated
with serial dilutions, one dilution per row, of one of the soluble
proteins, and wells in columns 7 to 12 are incubated with serial
dilutions of the other soluble protein variant. All wells are then
processed uniformly for ELISA detection.
p r o t e i ni nB u fAb yi n c u b a t i o na t4 ◦C sealed overnight.
Coating conducted at these protein concentrations is in
excess of the amount able to bind the plate well for most
proteins of 10–200kDa in size. The use of excess amount of
protein for coating exploits conditions to ensure saturated
coating to minimize variation of the assay.
Most small proteins or peptide fragments are suﬃciently
immobilized to the plate well to allow a robust assay. In
the case that simple hydrophobic absorption does not result
in a suﬃcient amount and strength of coating; microplates
with added reactive groups for covalent conjugation may be
considered (see Section 4.10).
4.4. Blocking of the Coated Plate. To begin protein binding,
the well contents of the microplate are emptied by shaking
into a sink, and the remaining solution removed by tapping
onto a stack of paper towels. The plate is then washed once
rapidly to avoid protein drying by the addition of a volume
of Buf T suﬃcient to ﬁll each well using a squishing bottle
(see Section 4.6). Following ﬁlling of the wells, the washing
buﬀer is emptied as above, tapped dry, and the wells are
blocked with 150µL/well 1% BSA in Buf T by incubation
at room temperature for 1hr sealed. When dealing with
limited protein material, the coating protein solution may be
recovered for reuse, although the resulting coating capacity
may decrease.
4.5. Protein Binding. Following empting of the blocking
solutionfromthewellsandtapping,theplateiswashedthree
t i m e sw i t hB u fTt or e m o v ef r e ep r o t e i n( s e eSection 4.6).
SerialdilutionsofthebindingpartnerproteinsolutioninBuf
B are then added to the wells at 100µL/well and incubated
with the immobilized protein at room temperature for 2hrs
sealed. A typical binding assay designed for myoﬁlament
proteins consists of free protein concentrations starting from
0.5–1µM and eight 3-fold serial dilutions (Figure 2).
4.6. Washing. Following protein-binding incubation, the
plate is washed as follows. The well contents are emptied by
shaking into the sink, the remaining solution is removed by
tapping onto paper towels, and the plate is washed a total of
three times with Buf T in a total period of 10min. The lag
time between emptying the well to ﬁlling with Buf T should
be as short as possible to avoid drying of the binding protein
on the plate resulting in high background.
Washing is conducted using a squishing bottle by ap-
plying a consistent stream of Buf T to sequentially ﬁll
the wells without overﬁlling. Accurate ﬁlling is critical for
the ﬁrst wash to avoid spilling over trace amount of the
binding protein between wells, especially from high to low
concentration and from positive to negative control wells.
It is useful to start the wash stream outside of the plate
and then move sequentially through the wells delivering
a continuing stream of wash solution while moving from
well to well. It is helpful to hold the plate slightly tilted,
beginning ﬁlling from the lower-side rows. This will help
avoid spillover from entering into empty wells without
further dilution. After the ﬁrst ﬁlling, the washing buﬀer
is immediately removed followed by the second wash. This
will limit the time for any spillover protein to interact at
a signiﬁcant concentration with the immobilized protein
in unwanted wells. The plate is then allowed to incubate
at room temperature for approximately 3min. The wash
procedure is repeated for the 3rd time and allowed to
incubate approximately 4min before ﬁnal removal of the
washing buﬀer as above.
The washing condition is an important factor in deter-
mining the eﬀectiveness and stringency of the assay by elim-
inating nonspeciﬁc binding while quantitatively evaluating
the dissociation of speciﬁc binding between the protein pair.
Using appropriate washing conditions will allow evaluating
the coupling strength of the two proteins studied. More
stringent separation by increasing the number of buﬀer
changes, duration of the washes, and/or the detergent con-
centration will diﬀerentially aﬀect weak and strong bindings
as a sensitive method to reveal diﬀerences among protein
variants of interest. It is worth noting that no single washing
condition ﬁts all protein-protein interactions, and the wash
strength should be evaluated empirically.
4.7. ELISA Detection. The partner protein speciﬁcally bound
to the immobilized protein is detected using an ELISA
procedure in which an antibody recognizing the partner6 Journal of Biomedicine and Biotechnology
protein is the primary reagent (Figure 1(a)). Following the
ﬁnal wash to remove unbound partner protein a predeter-
mined, constant dilution of the primary antibody in Buf
Bi sa d d e dt oa l lt h ew e l l sa t1 0 0 µL/well using a multi-
channel pipette and incubated sealed at room temperature
for 1hr. The working concentration of the primary antibody
should be predetermined to give a ﬁnal absorbance of
around 1.0 by ELISA titration against the partner protein
directly coated to a microplate in the same buﬀer system,
incubation, and washing conditions. The antibody solution
should be added quickly such that the well contents do
not dry out. The plate is then washed 3 times in 10min
as described in the Washing Section. A constant dilution
of HRP-conjugated second antibody against the primary
antibody in Buf B is added to all the wells at 100µL/well
and incubated at room temperature for 45min. Similar to
that of the primary antibody, the second antibody’s working
concentration should be determined empirically. The plate is
then washed 3 times in 10min as described in the Washing
Section (see Section 4.10) prior to adding 100µL/well of the
ABTS-H2O2 substrate solution.
The substrate reaction is incubated at room temperature
with periodic mixing (e.g., 2-3 seconds shaking in the plate
reader) and the color development monitored by absorbance
reading at 415 nm or 405 nm using a microplate reader at
several time intervals (e.g., 5, 10, 15, 20, 25, and 30min).
The well of highest absorbance is then plotted against time
and a time point chosen for analysis before deviation from
linear color development. Under typical assay conditions,
t h i sw i l lb eb e t w e e n1 0t o2 0m i n u t e so fd e v e l o p m e n t .T h e
time of development should also be such that the absorbance
reading remains within the reliable reading range of the
microplate reader, less than 2.0 for most instruments. If the
color development is too quick and the absorbance values
too high, the concentration of the primary and/or second
antibody should be decreased.
4.8. Data Analysis. Background absorbance for each serial
dilution of the binding protein is determined from 3 control
wells not coated with immobilized protein but processed the
same as the assays wells. Absorbance of the 3 control wells
is averaged, and this value is subtracted from data readings
for that dilution. Resultant absorbance values at the highest
concentration of each binding protein are averaged as the
maximum (100%) binding for that protein. It is important
to only compare the absolute values of the maximal binding
from experiments conducted at the same time to avoid
the eﬀect of day-to-day variations. Background-subtracted
absorbance values for each dilution of the binding protein
are then normalized to the average maximal binding value
and the titration curve plotted against a log scale of the
dilution concentrations. The curve is then ﬁt to determine
the soluble protein concentration required to reach 50%
maximal binding. Although it is best to compare the 50%
maximal binding values of protein variants from the same
assay, it is possible to compare day-to-day results as long as
thereagents,incubationtimes,washingstringency,androom
temperature remain consistent (Figure 3).
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Figure 3: A set of typical, original protein-protein binding curves
demonstrating the altered binding of an exon 8-excluded cardiac
troponin T (exon 8-excluded TnT, white square) to the interacting
protein troponin I in comparison with wild-type cardiac troponin
T (WT-TnT, black circle). The troponin T variants are conﬁgured
as the immobilized protein and troponin I the soluble protein.
The normalized binding curves demonstrate exon 8-excluded TnT
bound with higher aﬃnity to troponin I compared to WT-TnT
as evident by the lower concentration required for 50% maximal
binding. Absolute absorbance of the maximal binding is shown in
the inset demonstrating that both exon 8-excluded TnT and WT-
TnT exhibited similar coupling strength to troponin I.
T h ea b o v ep r o c e d u r ep r o v i d e sr e l a t i v ec o m p a r i s o n s
between two or more binding protein variants for their
interaction with the immobilized protein. With a standard
curve produced with known concentrations of the binding
partner protein, this approach can be employed to gain
quantiﬁcation of the partner in an unknown sample of
puriﬁed protein, body ﬂuid, or tissue homogenate.
4.9. Data Interpretation. The molar concentration required
for 50% maximal binding of the soluble partner protein
to the immobilized protein reﬂects the on-rate of their
association at equilibrium and is a representative of the
binding aﬃnity (Ka). Although the strength and time of
washing will aﬀect the nonequilibrium disassociation of the
binding protein, these conditions aﬀect all samples similarly.
Thus, the initial binding between the immobilized and free
proteins during equilibrium incubation is determined by the
intrinsic aﬃnity between the protein pair.
On the other hand, the level of maximal binding of the
solublepartnerproteintoagivenamountoftheimmobilized
protein represents their coupling strength or resistance
to the washes. In contrast to the maximally saturated
binding achieved during the equilibrium incubation step,
during washes the absence of free soluble binding protein
produces nonequilibrium dissociation. Thus, this coupling
strengthdeterminedinthesolid-phaseprotein-bindingassay
employing stringent washing-separation steps reﬂects the
oﬀ-rate of the protein pair’s binding. In the assay system,Journal of Biomedicine and Biotechnology 7
immobilized protein coating is conditioned to a maximum,
and binding of the partner protein at high concentration
reﬂects saturated binding. Therefore, similar to that in
aﬃnity chromatography, the disassociation resulting from
wash separation conditions is a highly sensitive measure
to provide information of the disassociation rate (Kd)o f
the protein pair studied. Washing strength can, therefore,
be altered to exploit coupling strength diﬀerences between
protein variants.
4.10. Optimizing Assay Conditions. A number of conditions
can be modiﬁed to optimize the solid-phase protein-binding
assay allowing investigation of a number of speciﬁc protein-
protein interactions, including nonmuscle proteins. Unlike
most traditional protein binding assays, a unique advantage
of the microplat-based protein binding assay is that it
allows diﬀerent buﬀer conditions during the incubation and
washing steps. For example, one may coat a low-solubility
protein to the plate by dissolving it in a modiﬁed coating
buﬀer containing high salt and/or 3–6M urea. The salt
and urea will then be washed away, and the following
binding assay can be performed in physiological buﬀers.
Another example is that reducing agents may be included for
coating and protein-binding steps but removed before the
antibody incubation steps (reducing agents will dissociate
the quaternary structure of immunoglobulins). Further
examples include the use of diﬀerent buﬀer conditions for
the equilibration protein-binding step and the washing steps
that determine the stringency for separately investigating
association and dissociation rates.
Other optimizations include adaptations for small pep-
tides. Small peptides that are weak in hydrophobic absorp-
tion may be immobilized as a conjugate with a carrier
protein. Small peptides may also be immobilized through a
speciﬁc interaction such as the use of biotin-streptavidin sys-
tem. Microtiter assay plates of varied surface chemistry can
be used to enhance the coating of the immobilized protein.
For example, covalent bonding of peptides can be achieved
via precoating the plate with a hydrophilic polymer such as
soluble dextran treated with 2,2,2-triﬂouroethanesulphonyl
chloride (tresyl chloride) to activate hydroxyl groups [16].
As discussed above, separation strength can be varied
by altering the number, time, or stringency of the washes
to exploit the properties of the interaction between the
protein pair studied. Issues of low amounts of protein
binding can be overcome by employing detection methods
of increased sensitivity. For example, higher concentrations
of the primary and/or secondary antibodies may be used.
Alternatively, instead of ABTS, o-phenylenediamine (OPD)
or 3,3 ,5 ,-tetramethylbenzidine (TMB) can be employed
as the substrate to increase detection sensitivity of weaker
binding protein pairs. If labeling a protein does not interfere
with its binding, the binding partner protein can directly be
labeled by conjugation to a ﬂuorescent tag and its binding to
the immobilized protein detected by measuring ﬂuorescence
of the bound protein.
Taken together the adaptability of the solid-phase
protein-binding assay oﬀers signiﬁcant ﬂexibility to develop
speciﬁcally optimized experiments allowing for the investi-
gation of a wide range of proteins under varied conditions.
5. ExtendedAssayConﬁgurations
As presented above, the simple binary protein-binding assay
can provide signiﬁcant information regarding diﬀerences in
the interaction of one protein with another. Additionally the
solid-phase protein-binding assay is amendable to provide
information on more than binary protein-protein interac-
tions. With appropriate optimization, other protein-protein
interactionsofincreasedcomplexitycanbestudiedusingthis
approach. One or both of the binding partners may be a
protein complex as long as a suitable antibody is available
for the ELISA detection [17]. This methodology can also be
readily applied to multilayer binding assays and competition
assays. In the multilayer binding assay an additional protein
binding step can be added to evaluate the binding among
the subunits of a multiprotein complex (Figure 1(b)). We
have successfully employed a similar multilayer assay in our
laboratory investigating the binding of tropomyosin and
troponinTinthepresenceofﬁlamentousactin(unpublished
data). Likewise, other multi-protein complexes or binding
cofactors could similarly be investigated.
Inthecompetitionassay,bindingofapartnerproteinata
constant concentration to the immobilized protein is carried
out in the presence of serial concentrations of a competitive
protein (Figure 1(c)). Using a speciﬁc primary antibody to
detectthepartnerprotein,itsaﬃnitytotheimmobilizedpro-
teinrelativetothatofthecompetitiveproteincanbeassessed.
The competition assay design can be modiﬁed to study the
blocking eﬀect of a protein, a peptide, or a small-molecule
ligand on the binding of the partner protein to the immo-
bilized protein. The competition assay is also applicable not
only to two proteins but also to two isoforms of the same
protein [18]o rd i ﬀerent posttranslational modiﬁcations [19]
to asses the eﬀect of the modiﬁcation on binding.
The competition assay is also amendable to study the
spatial relationship between a protein-binding site and an
antibody-binding site [19]. Using a monoclonal or anti-
peptide antibody against a known epitope of structural
and/or functional interests, the assay can be extended to
identifybindingpartnersoftheproteininacomplexmixture
through competitive blocking of the antibody epitope by
protein binding. Likewise, substrate-enzyme interactions
could be investigated using a similar competitive approach
by employing an antibody against the catalytic site. When an
antibody probe is available, the competitive assay conﬁgura-
tion is likewise applicable to study the interactions between
proteins and cofactors.
6. SpecialCautions
Although the solid-phase protein-binding assay is readily
amendable to a number of diﬀerent situations, a few key
points must be observed to ensure success. Importantly,
reducing agents must be excluded from all buﬀers for the
primary antibody incubation and subsequent steps. The8 Journal of Biomedicine and Biotechnology
inclusion of reducing agents in these steps will disrupt
immunoglobulindisulﬁdebondsdestroyingtheabilityofthe
antibody to detect the bound protein and, thus, rendering
no signal. Furthermore, although employing methods of
increased sensitivity can help with detection of low-aﬃnity
binding, this methodology, applying high stringent washes,
is most eﬀective in studying high-aﬃnity binding events.
7. Conclusions
We have presented detailed methodology of a novel solid-
phase binding assay to assess protein-protein interactions
emphasizing examples using muscle regulatory proteins.
This assay expands on previous methodologies to provide a
simple and high-throughput assay to assess protein-protein
interactions in solution. In contrast to many other current
methods that process a few samples a time, this approach
readily handles hundreds of assay wells by a single operator
in a days time using common laboratory equipment. By
employing the adaptations and optimizations discussed,
this assay should be readily applicable to the quantitative
assessment of other nonmuscle proteins interactions.
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